Myasthenic Syndromes, Congenital
IRA round 2 begins as drugmakers sign on to price negotiation process with CMS
Myasthenic Syndromes, Congenital, Mediation, Prices, Medicare, Ira (eukaryote), drugmakers
Trump’s Healthcare Nominees Pledge to Divest Industry Investments Amid Controversy
Trump administration, healthcare appointments, NIH, CMS, divestment, industry ties, Jay Bhattacharya, Mehmet Oz, Robert F. Kennedy Jr.
Massive Layoffs Sweep Federal Health Agencies: Thousands of Workers Impacted Across HHS
HHS layoffs, federal health agencies, probationary workers, Trump administration, workforce reduction, CDC, NIH, FDA, CMS
DOGE Access to Treasury Systems Restricted Amid Concerns Over CMS Scrutiny
Elon Musk, DOGE, Treasury Department, CMS, payment systems, privacy concerns, lawsuit, federal court order
Understanding the Second Round of Medicare Drug Price Negotiations: What Trump’s CMS Can and Can’t Change
Medicare drug price negotiation, Trump administration, CMS, Inflation Reduction Act, drug prices, negotiation process
CMS Approves Transitional Pass-Through Payments for Renal Denervation Systems from Medtronic and Recor Medical
Renal Denervation Systems, CMS, Transitional Pass-Through Payments, Medtronic, Recor Medical, Hypertension Treatment
CMS Unveils Preliminary List of 101 Generic Drugs for Medicare $2 Out-of-Pocket Plan
Medicare $2 Drug List Model, generic drugs, out-of-pocket costs, medication adherence, health outcomes, CMS Innovation Center
CMS Prepares for Second Round of Medicare Drug Price Negotiation Program
Medicare Drug Price Negotiation Program, CMS, drug price negotiations, Inflation Reduction Act, Part D drugs, maximum fair prices (MFPs)